Various antibody-based or peptide-based theranostic nanocarriers targeting VCAM-1, ICAM-1, E- and P-selectin, or platelet endothelial cell adhesion molecule (PECAM-1) are described in the literature to deliver their cargo to endothelial cells in in vitro and in vivo models of atherosclerosis [17,18,19,20]. The gene discussed is PECAM1; the disease is atherosclerosis.